# PERSEE (NCT04547504)

> PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04547504
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University Hospital, Brest
- Conditions: Non-small-cell Lung Cancer
- Interventions: Pembrolizumab; Pembrolizumab and Chemotherapy drugs
- Enrollment: 349
- Primary outcome: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=persee-nct04547504

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04547504", "email": "<work email>"}; the inbox owner confirms by the emailed link.